Results 161 to 170 of about 11,033 (240)

Future of Pharmacometrics

Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2018
openaire   +2 more sources

Assessment and Benchmarking of Model Informed Approaches in Drug Development for Hemoglobinopathies: A Review of Scientific Advices From January 2000 to December 2024. [PDF]

CPT Pharmacometrics Syst Pharmacol
Govere GS, Dogné JM, Musuamba F.
europepmc   +1 more source

The Role of Estradiol in Oxidative Stress in Health and Cystathionine ß-Synthase Deficiency: A Mechanistic Model. [PDF]

CPT Pharmacometrics Syst Pharmacol
Cruikshank A, Nijhout HF, Reed MC.
europepmc   +1 more source

Some Common Dose-Exposure-Response Estimands and Conditions for Their Causal Identifiability. [PDF]

CPT Pharmacometrics Syst Pharmacol
Bartels C, Wang Y, French J, Rogers J.
europepmc   +1 more source

Immunostimulatory and Immunodynamic Modeling Analysis to Determine a Plausible Starting Dose of mRNA-4359 for Use in First-In-Human Trials. [PDF]

CPT Pharmacometrics Syst Pharmacol
Greene SA, Channavazzala M, Paleja B, Sandhu HS, Kumar R, Attarwala H, Van L, Liang M.   +7 more
europepmc   +1 more source

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients. [PDF]

CPT Pharmacometrics Syst Pharmacol
Pham TN, Largajolli A, Sardu ML, Maringwa J, Zierhut ML, Cheung SYA.   +5 more
europepmc   +1 more source

Evaluating the Impact of Intestinal Bile Salts on Drug Absorption Using PBPK Modeling: Case Studies With Efavirenz, Cinnarizine, and Posaconazole. [PDF]

CPT Pharmacometrics Syst Pharmacol
Al-Amiry Santos LG, Polak S, Yeo KR.
europepmc   +1 more source

Conditional Versus Unconditional Covariate Effects in Pharmacometric Models: Implications for Interpretation, Communication, and Reporting. [PDF]

CPT Pharmacometrics Syst Pharmacol
Jonsson EN, Jönsson S, Hansson E, Nyberg J.   +3 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors. [PDF]

CPT Pharmacometrics Syst Pharmacol
Babel H, Brunsdon P, Engelhardt B, Schmitt V, Ratajczak C, Mensing S, Menon RM, Parikh A.   +7 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling in Patients With Hepatic Impairment: Are Changes in Bosutinib Exposure Profiles Driven by Altered Absorption or Distribution? [PDF]

CPT Pharmacometrics Syst Pharmacol
Muto C, Jones HM, Yamazaki S.
europepmc   +1 more source